Okajima M, Takamura M, Taniguchi T. Landiolol, an ultra-short-acting β1-blocker, is useful for managing supraventricular tachyarrhythmias in sepsis. World J Crit Care Med 2015; 4(3): 251-257 [PMID: 26261777 DOI: 10.5492/wjccm.v4.i3.251]
Corresponding Author of This Article
Masaki Okajima, MD, PhD, Intensive Care Unit, Kanazawa University Hospital, 13-1 Takaramachi, Kanazawa 920-8641, Japan. masaki46228@m-kanazawa.jp
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Clinical Trials Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Masaki Okajima, Takumi Taniguchi, Intensive Care Unit, Kanazawa University Hospital, Kanazawa 920-8641, Japan
Masayuki Takamura, Department of Disease Control and Homeostasis, Kanazawa University Graduate School of Medicine, Kanazawa 920-8641, Japan
Author contributions: Okajima M, Takamura M and Taniguchi T contributed to this manuscript.
Institutional review board statement: The study was reviewed and approved by the Kanazawa University Hospital Institutional Review Board.
Clinical trial registration: This study is registered at http://www.controlled-trials.com/isrctn/. The registration identification number is ISRCTN 70831305.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All authors state that they have no conflict of interest.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at masaki46228@m-kanazawa.jp.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Masaki Okajima, MD, PhD, Intensive Care Unit, Kanazawa University Hospital, 13-1 Takaramachi, Kanazawa 920-8641, Japan. masaki46228@m-kanazawa.jp
Telephone: +81-76-2652000 Fax: +81-76-2344339
Received: August 22, 2014 Peer-review started: August 22, 2014 First decision: September 28, 2014 Revised: April 15, 2015 Accepted: April 27, 2015 Article in press: April 29, 2015 Published online: August 4, 2015 Processing time: 360 Days and 17.1 Hours
Core Tip
Core tip: The management of tachyarrhythmia is important but it is often difficult because of unstable hemodynamics in septic patients. Landiolol is an ultra-short-acting β1 selective adrenoceptor antagonist. It exerts a more potent negative chronotropic effect and a lesser effect on blood pressure than other β blockers. In fact, landiolol significantly reduced heart rate without any deterioration of hemodynamics in this study. The most impressive finding is high conversion rate to sinus rhythm immediately after landiolol administration. Landiolol could control not only heart rate but also cardiac rhythm in septic patients with supraventricular tachyarrhythmias. Landiolol safely reduced heart rate and, in part, converted to sinus rhythm in septic patients with supraventricular tachyarrhythmia. Landiolol could be a valuable and suitable drug for managing supraventricular tachyarrhythmias in patients with sepsis.
